| Document |
Document Title |
|
WO/2024/084290A1 |
It is an object of he present invention a composition and a formulation containing said composition and, optionally, additives or excipients or carriers of acceptable food or pharmaceutical grade. Further, the present invention relates t...
|
|
WO/2024/085170A1 |
The purpose of the prevent invention is to develop and provide a drug for alleviating, resolving, remitting or treating a symptom of a patient who develops aftereffects of a viral infection. A tricyclic compound represented by general ...
|
|
WO/2024/085053A1 |
Provided is a composition that can form a powder having few aggregates, can form a powder having exceptional properties for re-dispersion in an aqueous medium, and moreover can form a powder having exceptional properties for re-dispersio...
|
|
WO/2024/082872A1 |
The present invention relates to a compound as represented by general formula Ⅰ, or a pharmaceutically acceptable salt, stereoisomer, ester, prodrug or solvate thereof. Experimental results indicate that the compound has high inhibitor...
|
|
WO/2024/086521A1 |
The present disclosure relates to methods for inducing rejuvenation in a population of glial progenitor cells and methods for treating a subject having a glial cell-related disorder. Methods include administering, to the population of ad...
|
|
WO/2024/085081A1 |
Provided is an antibody that specifically binds to the extracellular domain of human LPA1 but does not specifically bind to the extracellular domain of human LPA2 or the extracellular domain of human LPA3. The antibody preferably has act...
|
|
WO/2024/085805A1 |
The present invention relates to methods of treating diseases or conditions associated with abnormal levels of lamin B1 protein. Disclosed herein are methods of treating pathologies of lamin B1 accumulation, such as Adult-onset Autosomal...
|
|
WO/2024/086570A1 |
N-Biarylmethylene substituted pyrrolopyridinone, pyrrolopyrazinone, pyrrolopyrimidinone, and isoindolin-1-one compounds having a tertiary alcohol-containing group substituted on the biarylmethylene are positive allosteric modulators of t...
|
|
WO/2024/083822A1 |
In a first aspect the invention relates to a method for identifying a subject suffering from Alzheimer's dementia (AD) or being at risk of developing Alzheimer's dementia, the method comprising: (a) determining in a first body fluid samp...
|
|
WO/2024/083026A1 |
The present invention relates to the field of pharmaceutical formulations. Disclosed are a composition containing Lumateperone active ingredients, and a long-acting sustained-release formulation and a preparation method therefor. A compo...
|
|
WO/2024/085245A1 |
The purpose of the present invention is to provide a preparation that can effectively suppress post-operative delirium. A post-operative delirium suppressant according to the present invention is characterized by containing a GABA-A rece...
|
|
WO/2024/086179A1 |
The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more ...
|
|
WO/2024/084362A1 |
The present invention relates to a stable crystalline form of Tafamidis having characteristic 2-theta peaks at 13.6±0.2, 20.4±0.2 and 27.5±0.2. The present invention provides Tafamidis having particle size (d90) less than 100 microns....
|
|
WO/2024/083150A1 |
Disclosed in the present invention are a crystal form A of the NK3R antagonist represented by formula (I), and a preparation method therefor and the use thereof. The X-ray powder diffraction pattern of the crystal form A comprises charac...
|
|
WO/2024/083705A1 |
The present invention covers the use of furoindazole compounds of general formula (I): (I) in which R1, R2, R3, R4, R5, R6, R7a, and R7b are as defined herein, for the treatment or prophylaxis of diseases, in particular of inflammatory-d...
|
|
WO/2024/084400A2 |
The present disclosure relates generally to alpha 2 macroglobulin (A2M) protein and soluble Klotho (sKL) protein, compositions comprising same, and related uses (e.g., treating a coronavirus (e.g., severe acute respiratory syndrome coron...
|
|
WO/2024/086218A1 |
In one aspect, the present disclosure provides a method of synthesis for methylone HCl, with 3,4-methylenedioxypropiophenone (MDP) as the starting material. In another aspect, the present disclosure provides stereoisomers of methylone. I...
|
|
WO/2024/083176A1 |
Disclosed are the uses of amniotic fluid in the preparation of a drug for treating and/or preventing macrophage-mediated diseases, a drug for treating and/or preventing type M1 macrophage-mediated diseases, a drug for treating and/or pre...
|
|
WO/2024/083919A1 |
The present invention relates to use of inhibitors of the potassium channel Kv1.3 in therapeutic methods, in particular wherein the methods comprise administering the inhibitor to a subject at particular intervals.
|
|
WO/2024/083861A1 |
The present invention relates to 1-(sulfonyl)-N-phenylpyrrolidine-2-carboxamides derivatives according to formula (I) for use in the prevention and/or treatment of a disease or disorder selected from an autoimmune disease, organ transpla...
|
|
WO/2024/086182A1 |
The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or m...
|
|
WO/2024/086312A1 |
The present disclosure provides enhanced nicotinamide adenine dinucleotide (NAD+) compositions and pharmaceutical formulations, useful in the treatment of disorders and diseases regulated by deficiencies in NAD+, and methods of preparati...
|
|
WO/2024/086630A1 |
Methods of treating a subject with diabetes or Alzheimer's disease with a disclosed islet amyloid polypeptide (IAPP) isoform or peptide are provided. Methods of detecting IAPP isoforms or peptides are also provided.
|
|
WO/2024/085841A1 |
The invention falls within the technical fields of molecular neuropharmacology and relates to a biocompatible humanin-loaded solid lipid nanoparticle which allows the active ingredient to cross the blood-brain barrier in order to provide...
|
|
WO/2024/083146A1 |
The present invention relates to a compound of general formula (A) and a pharmaceutical composition thereof. The compound of formula (A) provided in the present invention can be used for preventing and/or treating diseases related to the...
|
|
WO/2024/083087A1 |
A sustained release osmotic-controlled pharmaceutical composition is provided, including: a core and a semi-permeable membrane coated on the core. The core includes a drug compartment, in which the drug compartment includes a first activ...
|
|
WO/2024/086491A1 |
Provided herein is 5-OMe-DALT hemisuccinate, including solid forms such as crystalline forms of 5-OMe-DALT hemisuccinate, useful in treatment of severe neurological disorders, severe pain, or addictive conditions. Also provided are pharm...
|
|
WO/2024/079314A1 |
The invention relates to a dosage regimen, method for treating, delivery device or parenteral formulation for use in the treatment of a psychiatric or neurological disorder in a patient. In particular, the invention relates to the admini...
|
|
WO/2024/079647A1 |
The present invention relates to a composition comprising at least one psychedelic tryptamine, preferably derived from psychedelic psilocybin mushrooms, more preferably from psychedelic psilocybin mushrooms belonging to the Psilocybe gen...
|
|
WO/2024/079221A1 |
An isolated protein comprising (i) a first protein moiety selected from the group of proteins comprising an amino acid sequence having at least 70% identity to residues 113-231 of 5 Bri2 from human (SEQ ID NO: 2); and proteins comprising...
|
|
WO/2024/078607A1 |
Provided in the present invention are a pharmaceutical composition for treating Parkinson's disease and a preparation method therefor. Compared to the reference preparation "Xining", the carbidopa and levodopa sustained-release tablet pr...
|
|
WO/2024/077893A1 |
Disclosed in the present invention are preparation of a combination of stem cells and a hydrogel as a biomaterial, and the use of the combination in spinal cord injuries. The preparation comprises the following steps: preparing methacryl...
|
|
WO/2024/079351A1 |
The present invention relates to a compound of general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof. The invention further relates to the use of the compounds of the invention as neuroprotective and/or neurore...
|
|
WO/2024/081604A1 |
The present relates to polynucleotide constructs encoding an ApoE3 related protein optionally containing one or more intron. Potential uses of the different constructs include gene therapy targeting one or more disease or disorder, for e...
|
|
WO/2024/080768A1 |
The present invention relates to a pharmaceutical composition for preventing or treating peripheral neuropathy, and the like. The present invention has been completed by confirming that an isoquinoline derivative discovered through a scr...
|
|
WO/2024/081168A1 |
This disclosure relates to the field of therapeutic tyrosine kinase inhibitors, in particular Bruton tyrosine kinase ("BTK") inhibitors for treatment of subjects with relapsing multiple sclerosis.
|
|
WO/2024/081959A2 |
The present disclosure presents compositions and methods for improving the condition of a subject, including improving cognitive function and mood effects. The composition comprises a first polyphenol and at least one essential oil(s), w...
|
|
WO/2024/079471A1 |
A prebiotic oligosaccharide composition for use in reducing the level of ammonia. The composition comprises oligosaccharide compounds, for example galactooligosaccharide compounds, which includes: (a) at least 8 wt% Gal-(β1-3)-Gal-(β1-...
|
|
WO/2024/079682A1 |
The present invention relates to a sulfoximine compound having a novel structure, stereoisomers thereof or pharmaceutically acceptable salts thereof, and a use thereof for preventing or treating histone deacetylase-mediated diseases The ...
|
|
WO/2024/078488A1 |
Disclosed in the present invention are a thiochroman derivative and a preparation method therefor and a use thereof. The structure of the thiochroman derivative is as shown in general formula (I), and the definition of each substituent i...
|
|
WO/2024/079342A1 |
The present invention relates to new pyrrolopyrimidines and purines which surprisingly act as CSF-1R inhibitors, to processes for making these compounds, and to uses thereof.
|
|
WO/2024/078373A1 |
The present invention relates to a use of jojoba oil in preparation of e-liquid of an electronic cigarette. The jojoba oil is used as a solvent in the process of preparing the e-liquid of an electronic cigarette. The present invention ha...
|
|
WO/2024/081934A1 |
Described herein are methods and compositions for treating Alzheimer's Disease (AD), as well as compositions comprising a reelin-derived peptide and methods of use thereof.
|
|
WO/2024/080440A1 |
The purpose of the present invention is to provide a composition for preventing or treating neurodegenerative disorders, comprising humanin peptide as an active ingredient. When the humanin peptide of the present invention was administer...
|
|
WO/2024/080721A1 |
The present invention relates to methods for the treatment of proteinpathies, more especially, methods of i) preventing or reducing protein aggregation, ii) reducing protein deposition, iii) reducing cytotoxicity induced by protein aggre...
|
|
WO/2024/081442A1 |
Soluble proteins and extracellular vesicles (EVs) produced by optic nerve lamina region neural progenitor cells (ONLR-NPCs) are provided. Such proteins and EVs include growth factors and survival factors that can be used in the treatment...
|
|
WO/2024/081828A1 |
Neuropsychiatric treatments, including methods, regimens, and interventions to reduce physical dependence to those neuropsychiatric treatments based on ulotaront administration.
|
|
WO/2024/079128A1 |
The invention relates to compounds and their therapeutic use, said compounds having the formula (I): wherein, for example, Z is representing a (II) X is representing a NR5R6 group wherein R5 and R6 are hydrogen, R1 is represe...
|
|
WO/2024/080323A1 |
Provided is a novel use of a composition that contains a prescribed sulfur-containing compound, a salt thereof, or both. The present invention is a sirtuin activator or expression enhancer, a NAD+ increasing agent, or a senescent cell in...
|
|
WO/2024/081404A1 |
The present disclosure is related to dietary supplements including compositions that include, one or more agents that increase γ-aminobutyric acid (GABA) binding with GABA-A receptor, increase serotonin concentrations, decrease dopamine...
|
